insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2018
051019902018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2013
2013
BACKGROUND The purpose of this study was to evaluate change in glycosylated hemoglobin (HbA1c), side effects, and quality of life… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2011
2011
Postprandial hyperglycemia is known to be associated with increasing cardiovascular mortality in type 2 diabetes mellitus… (More)
Is this relevant?
2009
2009
AIMS IMPROVE is an open-label, multinational, non-randomised, 26-week observational study designed to evaluate the safety and… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2009
2009
OBJECTIVES To estimate the cost-effectiveness of switching patients with poorly controlled type 2 diabetes mellitus from human… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2009
2009
AIMS The IMPROVE observational study evaluated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30… (More)
Is this relevant?
2008
2008
AIMS The IMPROVE study is a multinational, open-label, non-randomised, 26-week observational study assessing the safety and… (More)
Is this relevant?
2008
2008
AIM The Physicians' Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy (PRESENT) study aims to assess the safety and… (More)
Is this relevant?
2007
2007
BACKGROUND We sought to compare the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) given twice daily with once… (More)
Is this relevant?
2003
2003
OBJECTIVE Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… (More)
Is this relevant?